|
NZ576563A
(en)
*
|
2006-11-03 |
2012-09-28 |
Alphavax Inc |
Alphavirus and alphavirus replicon particle formulations and methods
|
|
US20090111099A1
(en)
*
|
2007-10-27 |
2009-04-30 |
Yongsheng Ma |
Promoter Detection and Analysis
|
|
US8067241B2
(en)
*
|
2009-08-26 |
2011-11-29 |
General Electric Company |
Method and apparatus for antigen retrieval process
|
|
DK2529020T3
(en)
*
|
2010-01-28 |
2018-08-06 |
Childrens Hospital Philadelphia |
SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
|
|
US9644187B2
(en)
|
2010-04-14 |
2017-05-09 |
Emd Millipore Corporation |
Methods of producing high titer, high purity virus stocks and methods of use thereof
|
|
WO2012018628A1
(en)
|
2010-07-26 |
2012-02-09 |
Board Of Regents, The University Of Texas System |
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
|
|
CA2829774C
(en)
*
|
2011-03-14 |
2019-09-24 |
National Research Council Of Canada |
Method of viral production in cells
|
|
JP6348064B2
(ja)
|
2011-11-22 |
2018-06-27 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
効率の高いトランスジーン送達のためのウイルスベクター
|
|
US20140349403A1
(en)
|
2011-12-12 |
2014-11-27 |
The Children's Hospital Of Philadelphia |
Large commercial scale lentiviral vector production system and vectors produced thereby
|
|
US9974850B2
(en)
|
2013-01-25 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Immunogenic compositions and uses thereof
|
|
BR112015031541A2
(pt)
|
2013-06-17 |
2017-07-25 |
De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport |
métodos para o impedimento da agregação de componentes virais
|
|
CN105765066B
(zh)
*
|
2013-11-29 |
2018-12-14 |
宝生物工程株式会社 |
用于定量腺伴随病毒的方法
|
|
ES2744565T3
(es)
|
2014-04-25 |
2020-02-25 |
Genethon |
Tratamiento de la hiperbilirrubinemia
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US10526583B2
(en)
|
2014-07-02 |
2020-01-07 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for purifying recombinant adeno-associated virus
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN119876138A
(zh)
|
2014-11-14 |
2025-04-25 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
CA3193811A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
SG11201704919SA
(en)
*
|
2015-01-13 |
2017-07-28 |
Alfa Wassermann Inc |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CA3005633C
(en)
|
2015-11-16 |
2023-11-21 |
Research Institute Of Nationwide Children's Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopathies
|
|
WO2017100676A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
PL3436593T3
(pl)
|
2016-03-28 |
2023-03-27 |
Ultragenyx Pharmaceutical Inc. |
Sposoby inaktywacji termicznej adenowirusów
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
KR102695908B1
(ko)
*
|
2016-07-21 |
2024-08-14 |
스파크 테라퓨틱스, 인코포레이티드 |
재조합 아데노-관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터
|
|
JP2019530737A
(ja)
|
2016-08-23 |
2019-10-24 |
アコーオス インコーポレイテッド |
ヒト対象において非加齢性聴力障害を治療するための組成物および方法
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
MX2019002842A
(es)
|
2016-09-12 |
2019-08-29 |
Genethon |
Variantes de alfa-glucosidasa acida y usos de las mismas.
|
|
US11166915B2
(en)
|
2016-09-16 |
2021-11-09 |
Leukocare Ag |
Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
PT3534922T
(pt)
*
|
2016-11-04 |
2024-06-07 |
Takeda Pharmaceuticals Co |
Formulações de vírus adenoassociado
|
|
US10626376B2
(en)
|
2016-11-14 |
2020-04-21 |
St. Jude Children's Research Hospital |
Method for isolating and purifying adeno-associated virus particles using salt
|
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
EP3576796A1
(en)
|
2017-02-01 |
2019-12-11 |
Centre National De La Recherche Scientifique |
Particles and compositions comprising the same for transfection
|
|
US11541131B2
(en)
|
2017-03-10 |
2023-01-03 |
Genethon |
Treatment of glycogen storage disease III
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
US20200263199A1
(en)
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
MX2020004830A
(es)
|
2017-11-08 |
2020-11-11 |
Avexis Inc |
Medios y metodo para preparar vectores virales y usos de los mismos.
|
|
EP3720500A4
(en)
*
|
2017-12-05 |
2021-08-25 |
Applied Genetic Technologies Corporation |
FORMULATION OPTIMIZATION FOR VIRAL PARTICLES
|
|
MX2020007876A
(es)
|
2018-01-31 |
2020-12-03 |
Res Inst Nationwide Childrens Hospital |
Terapia genica para la distrofia muscular de cinturas tipo 2c.
|
|
EP3749771A1
(en)
|
2018-02-07 |
2020-12-16 |
Genethon |
Hybrid regulatory elements
|
|
WO2019173434A1
(en)
|
2018-03-06 |
2019-09-12 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
CN112313331A
(zh)
|
2018-04-27 |
2021-02-02 |
沃雅戈治疗公司 |
用于测量aadc病毒载体效力的方法
|
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
|
CN112601557B
(zh)
|
2018-06-08 |
2025-06-06 |
诺华股份有限公司 |
用于测量药物产品效力的基于细胞的测定
|
|
MX2020014119A
(es)
|
2018-06-29 |
2021-06-18 |
Res Inst Nationwide Childrens Hospital |
Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
|
|
KR20240014102A
(ko)
*
|
2018-06-29 |
2024-01-31 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
AU2019299964A1
(en)
*
|
2018-07-11 |
2021-01-21 |
Takeda Pharmaceutical Company Limited |
AAV compositions
|
|
AU2019310459A1
(en)
|
2018-07-24 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
CA3107572A1
(en)
|
2018-08-08 |
2020-02-13 |
Genethon |
Mini-gde for the treatment of glycogen storage disease iii
|
|
EP3833745A1
(en)
*
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
CA3109432A1
(en)
|
2018-08-20 |
2020-02-27 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
MX2021010356A
(es)
|
2019-02-26 |
2022-03-04 |
Res Inst Nationwide Childrens Hospital |
SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
|
|
US20220162640A1
(en)
|
2019-04-08 |
2022-05-26 |
Genethon |
Hybrid promoters for muscle expression
|
|
US20220143115A1
(en)
|
2019-04-19 |
2022-05-12 |
Regenxbio Inc. |
Adeno-Associated Virus Vector Formulations and Methods
|
|
BR112021020888A2
(pt)
|
2019-04-19 |
2021-12-21 |
Genethon |
Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
WO2021014428A1
(en)
|
2019-07-25 |
2021-01-28 |
Novartis Ag |
Regulatable expression systems
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US20220325250A1
(en)
|
2019-08-14 |
2022-10-13 |
Leukocare Ag |
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
US11401530B2
(en)
|
2019-08-19 |
2022-08-02 |
The Catholic University Of America |
Bacteriophage-based artificial viruses for human genome remodeling
|
|
US11155835B2
(en)
|
2019-08-19 |
2021-10-26 |
The Catholic University Of America |
Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
|
|
PT4017871T
(pt)
|
2019-08-21 |
2024-04-22 |
Res Inst Nationwide Childrens Hospital |
Distribuição de vetor de vírus adeno-associado de alfasarcoglicano e o tratamento da distrofia muscular
|
|
TW202122582A
(zh)
|
2019-08-26 |
2021-06-16 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
AU2020362119A1
(en)
|
2019-10-07 |
2022-05-26 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
WO2021078833A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric polypeptides and uses thereof
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
KR102167829B1
(ko)
*
|
2020-02-10 |
2020-10-20 |
주식회사 이노테라피 |
아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
|
|
JP7807380B2
(ja)
|
2020-02-21 |
2026-01-27 |
アコーオス インコーポレイテッド |
ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
US20230212528A1
(en)
*
|
2020-06-02 |
2023-07-06 |
Janssen Biotech, Inc. |
Materials and methods for viral purification
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
AU2021320395A1
(en)
*
|
2020-08-07 |
2023-04-13 |
Janssen Biotech, Inc. |
Formulations for highly purified viral particles
|
|
US20230313152A1
(en)
|
2020-08-24 |
2023-10-05 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
US20230407328A1
(en)
|
2020-11-02 |
2023-12-21 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
JP2023552841A
(ja)
|
2020-12-09 |
2023-12-19 |
ジェネトン |
ライソゾーム酸性リパーゼバリアント及びその使用
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022208342A1
(en)
*
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
US20240240204A1
(en)
*
|
2021-05-07 |
2024-07-18 |
Board Of Regents, The University Of Texas System |
Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
|
|
CN117897492A
(zh)
|
2021-08-04 |
2024-04-16 |
吉尼松公司 |
用于肌肉和cns中的基因表达的杂合启动子
|
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
|
JP2023059858A
(ja)
|
2021-10-15 |
2023-04-27 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
|
|
US20250235554A1
(en)
|
2021-10-25 |
2025-07-24 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
EP4514839A1
(en)
|
2022-03-17 |
2025-03-05 |
Innoskel |
Hybrid promoters and their use in osteolysis syndrome
|
|
EP4511392A1
(en)
|
2022-03-17 |
2025-02-26 |
Innoskel |
Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
JP2025524363A
(ja)
|
2022-06-09 |
2025-07-30 |
ジェネトン |
糖原病ｉｉｉの処置のためのｎ末端短縮型ｇｄｅ
|
|
US20260085328A1
(en)
|
2022-09-08 |
2026-03-26 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202426017A
(zh)
*
|
2022-11-24 |
2024-07-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
非包膜病毒的藥物組合物
|
|
CN121420060A
(zh)
|
2023-06-29 |
2026-01-27 |
吉尼松公司 |
用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
|
|
EP4606892A1
(en)
|
2024-02-23 |
2025-08-27 |
Merck Patent GmbH |
Methods for the production of viral particles
|